[{"notes_id":"1_250","category":"5","subcategory":"2","title":"Factor V Leiden","body":"Factor V Leiden (<span class=\"concept\" data-cid=\"590\">activated protein C resistance<\/span>) is the most common inherited thrombophilia, being present in around 5% of the UK population. <br \/><br \/>It is due to a gain of function mutation in the Factor V Leiden protein. The result of the mis-sense mutation is that activated factor V (a clotting factor) is inactivated 10 times more slowly by activated protein C than normal. This explains the alternative name for factor V Leiden of activated protein C resistance,<br \/><br \/>Heterozygotes have a 4-5 fold risk of venous thrombosis. Homozygotes have a 10 fold risk of venous thrombosis but the prevalence is much lower at 0.05%.<br \/><br \/>Screening for factor V Leiden is not recommended, even after a venous thromboembolism. The logic behind this is that a previous thromboembolism itself is a risk factor for further events and this should dictate specific management in the future, rather than the particular thrombophilia identified.<br \/><br \/>The table below shows the prevalence and relative risk of venous thromboembolism (VTE) of the different inherited thrombophilias:<br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th>Condition<\/th><th>Prevalence<\/th><th>Relative risk of VTE<\/th><\/tr><\/thead><tbody><tr><td>Factor V Leiden (heterozygous)<\/td><td>5%<\/td><td>4<\/td><\/tr><tr><td>Factor V Leiden (homozygous)<\/td><td>0.05%<\/td><td>10<\/td><\/tr><tr><td>Prothrombin gene mutation (heterozygous)<\/td><td>1.5%<\/td><td>3<\/td><\/tr><tr><td>Protein C deficiency<\/td><td>0.3%<\/td><td>10<\/td><\/tr><tr><td>Protein S deficiency<\/td><td>0.1%<\/td><td>5-10<\/td><\/tr><tr><td>Antithrombin III deficiency<\/td><td>0.02<\/td><td>10-20<\/td><\/tr><\/tbody><\/table><\/div>","notes_hash":"2b9a7678c28beda6e0988bd81ec35f9f","knowledge_graph_node_id_link":0,"links":"","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/IDgK9xPo3no\" data-description=\"Factor V Leiden\" data-upvotes=\"1\" data-downvotes=\"1\" data-media=\"1100\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/IDgK9xPo3no\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/IDgK9xPo3no\" data-description=\"Factor V Leiden\" data-upvotes=\"1\" data-downvotes=\"1\" data-media=\"1100\">Factor V Leiden<\/a><\/td><\/tr><tr><td><span ><small>Osmosis - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1903\" data-mediaid=\"1903\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1903\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">1<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1903\" data-mediaid=\"1903\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1903\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1<\/span><\/td><\/tr><\/table>","concepts_for_notes":[],"category_name":"Infectious disease \/ Haematology \/ Immunology","subcategory_name":"Haematology","comment_count":4},"",[]]